Filtered By:
Condition: Thrombosis
Vaccination: Vaccines

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 145 results found since Jan 2013.

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021
CONCLUSION: Thrombosis with thrombocytopenia syndrome is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the 3 cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention.PMID:35038274 | DOI:10.7326/M21-4502
Source: Annals of Internal Medicine - January 17, 2022 Category: Internal Medicine Authors: Isaac See Allison Lale Paige Marquez Michael B Streiff Allison P Wheeler Naomi K Tepper Emily Jane Woo Karen R Broder Kathryn M Edwards Ruth Gallego Andrew I Geller Kelly A Jackson Shashi Sharma Kawsar R Talaat Emmanuel B Walter Imo J Akpan Thomas L Ortel Source Type: research

Arterial intracranial thrombosis as the first manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report
We describe a severe case of vaccine-induced immune thrombotic thrombocytopenia (VITT) after the first dose of the ChAdOx1 nCoV-19 vaccine leading to massive ischemic stroke.MethodsA 42-year-old woman developed acute left hemiparesis (NIHSS 12) 9  days after the first vaccine dose.ResultsThe blood tests revealed low platelets (70 103/ μL) and severe increment of D-dimer (70,745 ng/mL FEU). Brain non-contrast computed tomography and multiphasic CT angiography demonstrated a right middle cerebral artery occlusion. The patient was treated with primary thrombectomy, steroids, immunoglobulin, and fondaparinux. Despite the tr...
Source: Neurological Sciences - January 13, 2022 Category: Neurology Source Type: research

First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac)
We present four consecutive cases of CVT after receiving either Sinopharm or Sinovac vaccine, both of which are composed of an inactivated-virus. All the patients recovered well with anticoagulation and discharged with a good functional outcome. This is the first case series reporting CVT following the administration of these vaccines.
Source: Journal of Stroke and Cerebrovascular Diseases - January 13, 2022 Category: Neurology Authors: Sajid Hameed, Ayisha Farooq Khan, Sara Khan, Mohammad Wasay Tags: Short Communication Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) as treatm...
Source: Critical Care Medicine - December 20, 2021 Category: Emergency Medicine Tags: Online Review Article Source Type: research

Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
Conclusions Our estimated background rates help contextualise observed events of these potential adverse events of special interest and to detect potential safety signals related to COVID-19 vaccines.
Source: BMJ Open - December 17, 2021 Category: General Medicine Authors: Nasreen, S., Calzavara, A. J., Sundaram, M. E., MacDonald, S. E., Righolt, C. H., Pai, M., Field, T. S., Zhou, L. W., Wilson, S. E., Kwong, J. C. Tags: Open access, Public health, COVID-19 Source Type: research

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs
Eur J Med Chem. 2021 Dec 7;228:114035. doi: 10.1016/j.ejmech.2021.114035. Online ahead of print.ABSTRACTMany populations suffer from thrombotic disorders such as stroke, myocardial infarction, unstable angina and thromboembolic disease. Thrombus is one of the major threatening factors to human health and the prevalence of cardio-cerebrovascular diseases induced by thrombus is growing worldwide, even some persons got rare and severe blood clots after receiving the AstraZeneca COVID vaccine unexpectedly. In terms of mechanism of thrombosis, antithrombotic drugs have been divided into three categories including anticoagulants...
Source: European Journal of Medicinal Chemistry - December 13, 2021 Category: Chemistry Authors: Xiaoan Li Tiantian Guo Qian Feng Tiantian Bai Lei Wu Yubo Liu Xu Zheng Jianzhong Jia Jin Pei Shaoping Wu Yiming Song Yongmin Zhang Source Type: research

Unexplained arterial thrombosis: approach to diagnosis and treatment
We present a structured approach to diagnosis with consideration of common causes, including atherosclerosis and embolism, as well as uncommon causes, including medications and substances, vascular and anatomic abnormalities, systemic disorders, and thrombophilias. We highlight areas of management that have evolved within the past 5 years, including the use of dual-pathway inhibition in atherosclerotic disease, antithrombotic therapy selection in embolic stroke of undetermined source and left ventricular thrombus, the role of closure of patent foramen ovale for secondary stroke prevention, and the thrombotic potential of c...
Source: Atherosclerosis - December 10, 2021 Category: Cardiology Authors: Jori E May Stephan Moll Source Type: research

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data
In conclusion, both virus-based COVID-19 vaccines show more SAEs than BNT, but the frequency of the SAE type in the different age groups differs, suggesting that the mechanisms responsible of SAEs overlap only partly.PMID:34710832 | PMC:PMC8547775 | DOI:10.1016/j.jaut.2021.102742
Source: Journal of Autoimmunity - October 28, 2021 Category: Allergy & Immunology Authors: Luigi Cari Mahdieh Naghavi Alhosseini Paolo Fiore Sabata Pierno Sabrina Pacor Alberta Bergamo Gianni Sava Giuseppe Nocentini Source Type: research